Tag:
galvus
Latest Headlines
Latest Headlines
Jimenez counts on 7 drugs to take Novartis past Diovan
Maybe it's the rarefied Davos air or the long-range mountain views, but Novartis ( $NVS ) CEO Joe Jimenez is feeling optimistic about the post- Diovan future. After the Swiss drugmaker loses patent...
Novartis nabs Chinese OK for Lucentis, launches Galvus
Novartis ( $NVS ) has gotten a double boost in China. First, the government approved its eye drug Lucentis , and second, the company launched its diabetes medication Galvus. Lucentis, an injectable
DPP-4 inhibitors get spotlight at ADA meeting
Researchers are unveiling positive data at the American Diabetes Association's meeting for new DPP-4 inhibitors for diabetes. Takeda is the latest, demonstrating that its alogliptin can control blood
Developers: Politics behind slow approval process
Woodcock's defense, though, may seem particularly hard to accept at a slate of big pharma companies which have been able to win European approvals only to run straight into a roadblock at the U.S.
Novartis discovery chief departs in management shakeup
Restructuring under the gun of new generics and after being slammed by regulatory defeats, Novartis is bidding adieu to James Shannon, its chief of global drug development. In his place Novartis has
Novartis gets EU approval for troubled Galvus
Following a label change, Novartis has won EU approval for its trouble diabetes drug Galvus. It will be used in combination with some of the most frequently prescribed oral anti-diabetes medicines.
ALSO NOTED: Novartis gets E.U. nod on Galvus; J&J reps' whistleblower suit tossed out;
> European regulators granted a sigh of relief to Novartis when they OK'd the Swiss drugmaker's type 2 diabetes med Galvus. Report > Two former reps for Johnson & Johnson saw their
Novartis CEO: Galvus' future is uncertain
Long delayed by a wary FDA, Novartis CEO Daniel Vasella ( photo ) now says that the diabetes drug Galvus may never be refiled for approval in the U.S. Safety issues arising around liver enzyme levels
ALSO NOTED: Galvus gets EU committee nod; Merck appoints Vanderbilt official to board;
> The European Committee for Medicinal Products gave its blessing to Novartis' new diabetes med Galvus, after the company revised prescribing information to minimize liver-safety problems. The
ALSO NOTED: Houston develop plots biotech park; Galvus wins EU nod; OncoMethylome inks deal with Abbott; and much more...
> A Houston developer has acquired Tanox's old headquarters--110,000 square feet on 24 acres--and plans to develop it as a biotechnology park. Tanox developed the asthma drug Xolair. Report >
